PTJ
ESPR

Paul Tudor Jones’s Esperion Therapeutics ESPR Stock Holding History

Paul Tudor Jones’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,214
Closed -$116K – 2451
2024
Q1 		$116K Buy
+43,214
New +$105K ﹤0.01% 2087
2023
Q4 		– Sell
-72,525
Closed -$71.1K – 2498
2023
Q3 		$71.1K Hold
72,525
– – ﹤0.01% 2168
2023
Q2 		$101K Sell
72,525
-49,456
-41% -$69.1K ﹤0.01% 2294
2023
Q1 		$194K Buy
121,981
+37,032
+44% +$191K ﹤0.01% 2186
2022
Q4 		$529K Buy
84,949
+13,505
+19% +$96.6K 0.01% 1547
2022
Q3 		$479K Buy
71,444
+25,547
+56% +$175K 0.01% 1437
2022
Q2 		$292K Sell
45,897
-26,627
-37% -$151K 0.01% 1585
2022
Q1 		$337K Buy
72,524
+168
+0.2% +$721 0.01% 1491
2021
Q4 		$362K Buy
72,356
+1,785
+3% +$14.3K 0.01% 1700
2021
Q3 		$850K Buy
70,571
+41,237
+141% +$600K 0.01% 1268
2021
Q2 		$620K Hold
29,334
– – 0.01% 1087
2021
Q1 		$823K Sell
29,334
-9,446
-24% -$279K 0.02% 928
2020
Q4 		$1.01M Buy
38,780
+29,421
+314% +$881K 0.03% 697
2020
Q3 		$348K Buy
+9,359
New +$371K 0.02% 942
2019
Q3 		– Sell
-9,890
Closed -$460K – 1160
2019
Q2 		$460K Buy
9,890
+4,747
+92% +$223K 0.01% 736
2019
Q1 		$206K Sell
5,143
-5,531
-52% -$248K 0.01% 993
2018
Q4 		$491K Buy
+10,674
New +$514K 0.01% 600
2017
Q4 		– Sell
-42,954
Closed -$2.15M – 1128
2017
Q3 		$2.15M Buy
+42,954
New +$2.07M 0.05% 197
2015
Q4 		– Sell
-23,100
Closed -$545K – 1693
2015
Q3 		$545K Buy
+23,100
New +$1.45M 0.02% 726
2015
Q2 		– Sell
-5,903
Closed -$547K – 1535
2015
Q1 		$547K Buy
+5,903
New +$381K 0.02% 687
2013
Q4 		– Sell
-10,000
Closed -$189K – 1290
2013
Q3 		$189K Buy
+10,000
New +$168K 0.01% 745

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's ESPR Position: Q2 2024 in Review

Paul Tudor Jones sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 43,214 shares — an estimated $116K sold.

Paul Tudor Jones first reported a position in ESPR in Q3 2013 and held it in 21 quarters. The position peaked at $2.15M in Q3 2017. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Paul Tudor Jones reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 43,214 Esperion Therapeutics shares in Q2 2024, an estimated $116K.
  • Paul Tudor Jones first reported a position in Esperion Therapeutics in Q3 2013 and held it in 21 quarters.
  • Paul Tudor Jones's Esperion Therapeutics position peaked at $2.15M in Q3 2017.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Tudor Investment Corp's 13F filing for Q2 2024, filed 14 Aug 2024.